Carleon Capital Partners Lowers stake in IDEXX Laboratories (IDXX)

IDEXX Laboratories (IDXX) : Carleon Capital Partners reduced its stake in IDEXX Laboratories by 7.17% during the most recent quarter end. The investment management company now holds a total of 27,790 shares of IDEXX Laboratories which is valued at $3,083,578 after selling 2,146 shares in IDEXX Laboratories , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.IDEXX Laboratories makes up approximately 1.50% of Carleon Capital Partners’s portfolio.

Other Hedge Funds, Including , Dimensional Fund Advisors Lp reduced its stake in IDXX by selling 4,667 shares or 1.91% in the most recent quarter. The Hedge Fund company now holds 239,914 shares of IDXX which is valued at $26,059,459. IDEXX Laboratories makes up approx 0.01% of Dimensional Fund Advisors Lp’s portfolio.Congress Asset Management Co reduced its stake in IDXX by selling 465,567 shares or 99.42% in the most recent quarter. The Hedge Fund company now holds 2,724 shares of IDXX which is valued at $297,052. IDEXX Laboratories makes up approx 0.01% of Congress Asset Management Co’s portfolio.Intrust Bank Na reduced its stake in IDXX by selling 65 shares or 0.79% in the most recent quarter. The Hedge Fund company now holds 8,134 shares of IDXX which is valued at $878,228. IDEXX Laboratories makes up approx 0.35% of Intrust Bank Na’s portfolio.Checchi Capital Advisers boosted its stake in IDXX in the latest quarter, The investment management firm added 22 additional shares and now holds a total of 696 shares of IDEXX Laboratories which is valued at $65,730. IDEXX Laboratories makes up approx 0.02% of Checchi Capital Advisers’s portfolio. Farmers Merchants Investments Inc added IDXX to its portfolio by purchasing 300 company shares during the most recent quarter which is valued at $28,575.

IDEXX Laboratories closed down -0.13 points or -0.12% at $110.81 with 3,06,836 shares getting traded on Wednesday. Post opening the session at $111.41, the shares hit an intraday low of $110.36 and an intraday high of $111.41 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, IDEXX Laboratories reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $466.56 million for the quarter, compared to analysts expectations of $445.57 million. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.

Many Wall Street Analysts have commented on IDEXX Laboratories. Company shares were Reiterated by Stifel on Aug 16, 2016 to “Buy”, Firm has raised the Price Target to $ 125 from a previous price target of $120 .IDEXX Laboratories was Upgraded by Northcoast to ” Neutral” on Aug 3, 2016. Company shares were Reiterated by Canaccord Genuity on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 98 from a previous price target of $90 .

IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *